J.P. Morgan analyst Casey Woodring maintained a Buy rating on Icon (ICLR – Research Report) on February 1 and set a price target of $265.00.

TD Cowen adjusted its financial outlook for ICON plc (NASDAQ:ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology, and medical device industries.

ICON (NASDAQ:ICLR) stock fell 8% early Tuesday after it issued financial guidance for 2025. The clinical research organization said that it expects to report 2025 revenue of $8.05B to $8.650B ...